Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02259478
Other study ID # 14-8191-CE
Secondary ID
Status Completed
Phase N/A
First received August 29, 2014
Last updated March 10, 2017
Start date October 2014
Est. completion date December 2016

Study information

Verified date March 2017
Source Toronto Transfusion Medicine Collaborative
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients at high risk of IVIG-associated hemolysis (defined as receipt of a 28-day cumulative dose of ≥ 2 g/kg, adjusted for ideal body weight, and non-O blood group) will be prospectively monitored using a standardized protocol for signs of hemolysis, and will be undergo additional testing for variables that have been hypothesized to increase the risk of hemolysis. The goal of the study is to define the incidence and dynamics of IVIG-mediated hemolysis and identify patient and product-related factors that may predict which patients are especially at risk.


Description:

All IVIG orders received by the blood transfusion service at participating sites will be screened for patient eligibility. All non-O blood group patients receiving a cumulative 28-day dose of IVIG ≥ 2 g/kg will be approached for enrolment. Exclusion criteria include the presence of an alternate cause of anemia, including blood loss, other drug-induced hemolysis, anemia associated with chemotherapy for cancer, or hemolysis associated with an underlying disease or participation in another ongoing study. Patients receiving repeated courses of therapy will be eligible for re-enrollment a maximum of 6 times. There are otherwise no exclusions on the basis of age, diagnosis, concurrent treatment, or specific brand of product received. Enrolment will occur at multiple Canadian health care facilities.

Upon enrolment,case report forms documenting the participant's previous medical history, IVIG treatments and adverse reactions, and concurrent medication use will be collected. Laboratory testing for hemolysis will be performed at baseline, immediately following the completed high-dose cycle (usually administered over 1-2 days), and then again at 5-10 days post-infusion. IVIG associated. Hemolysis will be defined and graded as per the criteria of the Canadian IVIG Pharmacovigilance Group. The pathophysiology of IVIG-associated hemolysis will be characterized by tracking changes in serum complement levels, performing extended cytokine profiling, and conducting mononuclear phagocyte activity assays using patient monocytes. Secretor gene status, ABO zygosity and FcR polymorphisms will also be determined. A predictive model incorporating both patient factors (eg., blood group, total dose prescribed, presence of pre-infusion inflammation) and product factors (eg., specific lot number) will then be developed.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 3 Months and older
Eligibility Inclusion Criteria:

- cumulative dose within a 28-day period equal or greater to 2 g/kg body weight, adjusted for lean body mass

- non-O blood group

- willing to provide blood samples immediately prior to, immediately after the completion of, and 5-10 days after the course of IVIG therapy

- Able to provide informed consent, either themselves or through a surrogate decision-maker

Exclusion Criteria:

- evidence of active bleeding or hemolytic anemia at time of enrolment (patients with chronic, stable anemia will be eligible following review by the principle investigator)

- concurrently prescribed transfusion therapy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Mount Sinai Hospital Toronto Ontario
Canada St. Michael's Hospital Toronto Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada The Hospital for Sick Children Toronto Ontario
Canada University Health Network Toronto Ontario
Canada Women's College Hospital Toronto Ontario

Sponsors (7)

Lead Sponsor Collaborator
Toronto Transfusion Medicine Collaborative Mount Sinai Hospital, New York, St. Michael's Hospital, Toronto, Sunnybrook Health Sciences Centre, The Hospital for Sick Children, University Health Network, Toronto, Women's College Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemolysis Definition and grading of hemolysis adopted from the Canadian IVIG Hemolysis Pharmacovigilance Group From initiation of IVIG therapy to 5-10 days after the completion of last IVIG infusion
Secondary Adverse transfusion reaction Any patient symptom reported during or within 10 days of an IVIG infusion will be considered as a possible adverse transfusion reaction. Symptoms deemed to most likely indicate an adverse reaction include the development of fever, chills or rigours; allergic reactions (urticaria, angioedema or anaphylaxis); pain reactions (including headache); respiratory symptoms (cough, shortness of breath); and signs suggestive of anemia or hemolysis (pallor, fatigue, red-coloured urine, jaundice) From initiation of IVIG therapy to 5-10 days after the completion of last IVIG infusion
Secondary Descriptive analysis of risk factors Additional secondary outcomes will include a descriptive analysis of information collected on the initial case report form such as patient demographics, medical history, dose and lot of IVIG administered, infusion rate, patient blood group, and concurrent medications. In addition, patient samples will be sent for additional testing aimed at elucidating the mechanism of IVIG-mediated hemolysis. These include:
Cytokine panel profiling
C3, C4, ferritin and CRP levels
Monocyte monolayer assay using patient monocytes and implicated lot of IVIG against AET-treated group A1, B, and O red cells
Tests of eluted IgG antibody for subtype.
ABO zygosity (PCR) and/or by Flow
FcR polymorphisms by PCR
Secretor status by PCR
From initiation of IVIG therapy to 5-10 days after the completion of last IVIG infusion
See also
  Status Clinical Trial Phase
Completed NCT03439605 - Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency N/A
Completed NCT03434145 - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases N/A
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Not yet recruiting NCT01201174 - Hemolysis in Patients With Hereditary Spherocytosis (HS) N/A
Completed NCT03582592 - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis N/A
Not yet recruiting NCT05754294 - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Completed NCT02996786 - Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners N/A
Not yet recruiting NCT05647200 - Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass, Part II N/A
Completed NCT05962268 - The Effect Of Vıdeo-Based Fıstula Care Educatıon On Hemodıalysıs N/A
Recruiting NCT06223802 - Biodex Training in Hemodialysis Females With Osteopenia N/A
Active, not recruiting NCT00792779 - Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty N/A
Not yet recruiting NCT06096428 - Hemolysis During Pulsed-field and Radiofrequency Ablation
Recruiting NCT03330223 - Effect of Haemodialysis on the Efficacy of Antiplatelet Agents N/A
Completed NCT04203784 - Meropenem and Piperacillin Plasma Concentrations During CRRT
Completed NCT06215339 - Diet Therapy in Hemodialysis Patients N/A
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Recruiting NCT03633435 - Home Hemodialysis Assisted by a Nurse for Arterio-venous Fistula Cannulation N/A
Withdrawn NCT02217683 - Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion Phase 2
Completed NCT03199612 - Sildenafil To Prevent Clot Early Phase 1
Completed NCT02711332 - Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling N/A